• First revenue in the U.S. for the use of Salix® Coronary Anatomy platform
• Five-year commercial agreement signed with Tanner Health, value at US$0.6M
• Agreement provides pathway for additional revenue from Salix® Coronary Plaque and Salix® Coronary Flow modules

Artrya Limited (ASX: AYA) has announced its first revenue in the U.S. market with a five-year commercial agreement signed with Tanner Health for the use of its Salix® Coronary Anatomy platform. The agreement, valued at US$0.6M, provides a SaaS licence with a monthly subscription fee for the Salix® Coronary Anatomy platform over 60 months. It also includes provisions for future fee-per-scan revenues once additional modules such as Salix® Coronary Plaque and Salix® Coronary Flow receive FDA clearance, which are both eligible for U.S. reimbursement under Category 1 CPT codes. The Salix® Coronary Anatomy platform has been successfully integrated into Tanner Health's Picture Archiving and Communications System (PACS) and Electronic Medical Record (EMR) systems and will now be available for clinical use on their patients with known or suspected coronary artery disease who have undergone a coronary CT angiogram. Artrya is also actively progressing commercial discussions with additional U.S. hospital networks and preparing for the FDA clearance and commercial launch of the Salix® Coronary Plaque module, which will further expand its platform offering and revenue base.

Artrya expects to generate additional revenue from the Salix® Coronary Plaque and Salix® Coronary Flow modules once they receive FDA clearance. The five-year commercial agreement with Tanner Health is valued at US$0.6M.

Artrya is actively progressing commercial discussions with additional U.S. hospital networks and preparing for the FDA clearance and commercial launch of the Salix® Coronary Plaque module, which will further expand its platform offering and revenue base.